{"organizations": [], "uuid": "2dd812c167d2ccf4d643b350ab376da33f2c970b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-boston-scient-results/boston-scientific-posts-quarterly-loss-due-to-tax-charge-idUSKBN1FL4XU", "country": "US", "domain_rank": 408, "title": "CORRECTED-UPDATE 1-Boston Scientific's sales beat, forecasts 2018 revenue above estimates", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-01T16:00:00.000+02:00", "replies_count": 0, "uuid": "2dd812c167d2ccf4d643b350ab376da33f2c970b"}, "author": "", "url": "https://www.reuters.com/article/us-boston-scient-results/boston-scientific-posts-quarterly-loss-due-to-tax-charge-idUSKBN1FL4XU", "ord_in_thread": 0, "title": "CORRECTED-UPDATE 1-Boston Scientific's sales beat, forecasts 2018 revenue above estimates", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "boston scientific", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "thomson reuters i/b/e/s.  boston scientific", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "boston scientific corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 1, 2018 / 11:42 AM / in 2 hours Boston Scientific's sales beats, forecasts 2018 revenue above estimates Reuters Staff 2 Min Read \n(Reuters) - Boston Scientific Corp ( BSX.N ) on Thursday forecast better-than-expected 2018 revenue after the medical device maker’s fourth-quarter sales beat Wall Street estimates on strong demand for its devices such as pacemakers and stents. \nThe company said it expects a revenue of between $9.65 billion and $9.80 billion and adjusted earnings per share of $1.35 to $1.39 in 2018. \nAnalysts on average forecast earnings per share of $1.38 on a revenue of $9.61 billion in 2018, according to Thomson Reuters I/B/E/S. \nBoston Scientific reported a net loss of $615 million, or 45 cents per share, in the fourth quarter ended Dec. 31, compared with a profit of $124 million, or 9 cents per share, a year earlier. \nIn the reporting quarter, the company incurred a $842 million charge due to changes in the U.S. tax law. \nThe company’s adjusted earnings of 34 cents per share were in line with the average analyst estimate. \nNet sales rose 10 percent to $2.41 billion, beating the average estimate of $2.38 billion. Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur", "external_links": [], "published": "2018-02-01T16:00:00.000+02:00", "crawled": "2018-02-01T16:09:45.027+02:00", "highlightTitle": ""}